Form 4 for ORMP ORAMED PHARMACEUTICALS INC.
Accepted 2026-01-05 00:00:00 ET · period of report 2025-12-31 · accession 0001213900-26-001275 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-01-05 | 2025-12-31 | ORMP | Mayer Arie | Dir | A - Grant | — | +34.9K | 168.0K | +26% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-31 | A | A | 30,000 | — | 163,109 | D | — | — | (F1) Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in three annual tranches beginning January 1, 2027. Each RSU represents the right to receive one share of common stock, par value $0.012 per share ("Common Stock"), of the Issuer. |
| 2 | Common | Common Stock | 2025-12-31 | A | A | 4,900 | — | 168,009 | D | — | — | (F2) Represents RSUs. The RSUs will vest in quarterly installments over a one-year period starting April 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer. |